Medtronic Talent Thoracic Stent Shows Aptitude In Limiting Mortality
This article was originally published in The Gray Sheet
Executive Summary
Results of Medtronic's VALOR trial show that 30-day all-cause mortality with the firm's recently launched Talent endovascular thoracic stent graft was 2% versus 8% for patients undergoing open surgery to repair thoracic aortic aneurysms
You may also be interested in...
Medtronic Talent thoracic stent graft debuts
Endovascular thoracic stent graft launches June 8 at the Society for Vascular Surgery annual meeting in San Diego following FDA approval, announced June 5. The device is indicated to treat aneurysms of the descending thoracic aorta. The firm simultaneously unveiled its Talent abdominal aortic stent graft, approved by FDA in April. Major competitors in both the thoracic and abdominal stent graft space are Cook Medical, which gained approval for its Zenith TX2 thoracic aortic aneurysm graft May 21, and W.L. Gore
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.